Panelists discuss how effective patient education, coordinated multidisciplinary care, strong caregiver advocacy, and proactive management of talquetamab’s unique adverse effects through standardized protocols and comprehensive handouts enable patients with relapsed/refractory multiple myeloma to successfully navigate bispecific antibody therapy while maintaining quality of life.
